Syntrix

Illumina has asked a federal court to dismiss a six-month-old trademark infringement lawsuit against Illumavista Biosciences following an apparent out-of-court settlement.

While Syntrix Biosystems may have played a role in developing foundational microarray technology, the company does not intend to use a large, recently awarded royalty payment from Illumina to expand its presence in the array market.

This story was originally posted on March 15.

NEW YORK (GenomeWeb News) – A federal court jury has ordered Illumina to pay $96 million in damages to Syntrix Biosystems in a patent infringement case.

A jury is considering whether Illumina has infringed the intellectual property of Syntrix, a company with whom the San Diego vendor discussed a potential business relationship more than a decade ago.

Illumina denies that its arrays infringe Syntrix's IP and has asked the court to declare that the patent at the heart of the case is invalid and that the suit be dismissed with prejudice.

In the suit, Syntrix alleges that Illumina has based its array products on technology developed originally by Syntrix and provided confidentially to Illumina a decade ago while the two firms were discussing a possible business relationship.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.